• LAST PRICE
    3.2450
  • TODAY'S CHANGE (%)
    Trending Up0.0750 (2.3659%)
  • Bid / Lots
    3.2300/ 1
  • Ask / Lots
    3.2600/ 3
  • Open / Previous Close
    3.1900 / 3.1700
  • Day Range
    Low 3.1200
    High 3.4599
  • 52 Week Range
    Low 0.9547
    High 3.4599
  • Volume
    111,244
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Tuesday's close: 3.17
TimeVolumeSPRB
09:32 ET54313.1899
09:33 ET5563.1889
09:39 ET4003.16
09:42 ET3003.165
09:50 ET2383.18
09:51 ET3063.19
09:55 ET13993.16
10:00 ET9673.19
10:02 ET38133.2292
10:04 ET378003.33
10:06 ET8263.3422
10:08 ET140153.17
10:09 ET119003.13
10:11 ET18503.14
10:18 ET2003.1427
10:22 ET1003.16
10:24 ET2503.1621
10:26 ET2003.1693
10:27 ET4003.1528
10:33 ET13003.14
10:40 ET1003.16
10:42 ET22003.19
10:51 ET1003.1819
11:00 ET1003.1588
11:02 ET5003.2
11:09 ET56003.23
11:12 ET41103.2999
11:14 ET12623.2989
11:16 ET6003.31
11:18 ET34273.29
11:27 ET1503.2887
11:30 ET32003.23
11:36 ET1003.245
11:39 ET1003.245
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesSPRB
Spruce Biosciences Inc
74.7M
-1.7x
---
United StatesVIRX
Viracta Therapeutics Inc
74.9M
-1.5x
---
United StatesMBIO
Mustang Bio Inc
75.5M
-0.9x
---
United StatesANEB
Anebulo Pharmaceuticals Inc
75.6M
-9.0x
---
United StatesINKT
Mink Therapeutics Inc
75.7M
-2.9x
---
United StatesTALS
Talaris Therapeutics Inc
73.6M
-1.0x
---
As of 2023-02-08

Company Information

Spruce Biosciences, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. The Company is initially developing its wholly owned product candidate, Tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). The Company is also developing Tildacerfont for women suffering from a rare form of polycystic ovary syndrome (PCOS) with primary adrenal androgen excess. The Company has initiated CAHmelia-203, a placebo-controlled, double-blind Phase IIb clinical trial in adult patients with classic CAH with poor disease control and anticipate topline. It has also initiated CAHmelia-204, a second Phase IIb clinical trial in adult patients with classic CAH with good disease control focused on glucocorticoid reduction and anticipate topline.

Contact Information

Headquarters
2001 Junipero Serra Blvd., Suite 640DALY CITY, CA, United States 94104-5401
Phone
302-636-5400
Fax
302-636-5454

Executives

Executive Chairman of the Board
Michael Grey
President, Chief Financial Officer
Samir Gharib
Chief Executive Officer, Director
Javier Szwarcberg
Vice President - Clinical Development
Saba Sile
Chief Medical Officer
Ralph Charlton

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$74.7M
Revenue (TTM)
$0.00
Shares Outstanding
23.6M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-1.88
Book Value
$4.74
P/E Ratio
-1.7x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.